VM202 is a DNA-based medicine meant to treat ischemic cardiovascular diseases via therapeutic angiogenesis.
VM501 is a re-engineered form of interleukin 11 (IL-11) targeting chemotherapy-induced thrombocytopenia (CIT) that is said to be less toxic than the existing FDA-approved drugs [REF].